



## Cartesian Therapeutics to Participate in Upcoming Investor Conferences

August 28, 2025

FREDERICK, Md., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the "Company"), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that its management expects to participate in the following investor conferences in September:

- A fireside chat at the Cantor Global Healthcare Conference 2025 at 11:30 a.m. ET on Thursday, September 4, 2025
- A fireside chat at Morgan Stanley's 23<sup>rd</sup> Annual Healthcare Conference at 4:05 p.m. ET on Tuesday, September 9, 2025
- A presentation at the H.C. Wainwright 27<sup>th</sup> Annual Global Investment Conference at 8:30 a.m. ET on Wednesday, September 10, 2025

Live webcasts of the fireside chats and presentation are expected to be accessible in the Events section of the Company's website at [www.cartesiantherapeutics.com](http://www.cartesiantherapeutics.com), where an archived replay of the events will also be available for a limited time.

### About Cartesian Therapeutics

Cartesian Therapeutics is a clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. The Company's lead asset, Descartes-08, is a CAR-T in Phase 3 clinical development for patients with generalized myasthenia gravis and Phase 2 development for systemic lupus erythematosus, with a Phase 2 basket trial planned in additional autoimmune indications. The Company's clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-BCMA CAR-T currently being evaluated in a Phase 1 trial in patients with multiple myeloma. For more information, please visit [www.cartesiantherapeutics.com](http://www.cartesiantherapeutics.com) or follow the Company on [LinkedIn](#) or [X](#), formerly known as Twitter.

### Investor Contact

Megan LeDuc  
Associate Director, Investor Relations  
[megan.leduc@cartesiantx.com](mailto:megan.leduc@cartesiantx.com)

### Media Contact

David Rosen  
Argot Partners  
[david.rosen@argotpartners.com](mailto:david.rosen@argotpartners.com)



Source: Cartesian Therapeutics, Inc.